On Jun 26, 2018 3.95 % to Target, Natera (NASDAQ:NTRA) Stock “Overweight” Rating Reconfirmed by Morgan Stanley.

June 26, 2018 - By Sarah Holford

Natera, Inc. (NASDAQ:NTRA) Corporate Logo

Reiterated Natera (NASDAQ:NTRA) Rating.

New York: On 25 June, a research report was revealed to investors of Natera (NASDAQ:NTRA). Its “Overweight” Rating reconfirmed by Morgan Stanley. Expert analysts have TP of $20 which means 3.95 % upside potential on firm’s stock.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

In total 4 analysts cover Natera (NASDAQ:NTRA). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $20 highest and $16 lowest price target Natera has $18.25 average price target or -5.15% below the current ($19.24) price. 7 are the (NASDAQ:NTRA)’s analyst reports since March 14, 2018 according to StockzIntelligence Inc. In Wednesday, May 9 report Morgan Stanley maintained it with “Overweight” rating and $16 target. On Monday, June 25 the stock of Natera, Inc. (NASDAQ:NTRA) earned “Buy” rating by Canaccord Genuity. The company rating was maintained by Craig Hallum on Friday, June 22. On Wednesday, March 14 the stock has “Buy” rating by Robert W. Baird. The stock rating was maintained by Morgan Stanley with “Overweight” on Monday, June 25. On Wednesday, March 14 Canaccord Genuity maintained the shares of NTRA in report with “Buy” rating.

Ticker’s shares touched $19.24 during the last trading session after 1.26% change.Natera, Inc. is uptrending after having risen 12.60% since June 26, 2017. NTRA has 1.27 million volume or 460.36% up from normal. NTRA outperformed the S&P 500 by 0.03%.

On August, 14 is awaited Natera, Inc. (NASDAQ:NTRA)’s earnings report, according to Zacks. earnings per share of $-0.53 is 1.92 % down from 2017’s $-0.52 EPS. Last quarter $-0.61 earnings per share was reported. Analysts predicts -13.11 % EPS growth this quarter.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services.The company has $1.05 billion market cap. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.Last it reported negative earnings. The firm also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

For more Natera, Inc. (NASDAQ:NTRA) news posted briefly go to: Benzinga.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “44 Biggest Movers From Yesterday” posted on June 26, 2018, “50 Biggest Movers From Friday” on June 25, 2018, “Key events next week – healthcare” with a publish date: June 21, 2018, “Stocks To Watch: More Trade Tiffs And Stress Tests” and the last “Natera (NTRA) Announces Powerful Kidney Transplant Rejection Biomarker” with publication date: June 21, 2018.

Natera, Inc. (NASDAQ:NTRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.